PMS-CLINDAMYCIN CAPSULE

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE)

Disponibbli minn:

PHARMASCIENCE INC

Kodiċi ATC:

J01FF01

INN (Isem Internazzjonali):

CLINDAMYCIN

Dożaġġ:

150MG

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

LINCOMYCINS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0105830002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2016-10-26

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
PR
PMS-CLINDAMYCIN
clindamycin hydrochloride capsules, USP
clindamycin 150 mg, 300 mg
ANTIBIOTIC
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite 100
July 13, 2016
Montréal, Québec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO.: 195698
_pms-CLINDAMYCIN Product Monograph_ Page 2 of 28_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
10
OVERDOSAGE
........................................................................................................................
11
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
12
STORAGE
AND
STABILITY..................................................................................................
13
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
15
PHARMACEUTICAL
INFORMATION
.................................................................................
15
DETAILED
PHARMACOLOGY...............................................